JPWO2019138367A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019138367A5 JPWO2019138367A5 JP2020538785A JP2020538785A JPWO2019138367A5 JP WO2019138367 A5 JPWO2019138367 A5 JP WO2019138367A5 JP 2020538785 A JP2020538785 A JP 2020538785A JP 2020538785 A JP2020538785 A JP 2020538785A JP WO2019138367 A5 JPWO2019138367 A5 JP WO2019138367A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cooh
- hydrogen
- virus
- conh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211350A JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841001438 | 2018-01-12 | ||
| IN201841001438 | 2018-01-12 | ||
| PCT/IB2019/050219 WO2019138367A1 (en) | 2018-01-12 | 2019-01-11 | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211350A Division JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021514345A JP2021514345A (ja) | 2021-06-10 |
| JP2021514345A5 JP2021514345A5 (https=) | 2022-01-18 |
| JPWO2019138367A5 true JPWO2019138367A5 (https=) | 2022-01-18 |
| JP7438955B2 JP7438955B2 (ja) | 2024-02-27 |
Family
ID=67213573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538785A Active JP7438955B2 (ja) | 2018-01-12 | 2019-01-11 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
| JP2023211350A Active JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211350A Active JP7698699B2 (ja) | 2018-01-12 | 2023-12-14 | Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11274123B2 (https=) |
| EP (1) | EP3737401A4 (https=) |
| JP (2) | JP7438955B2 (https=) |
| KR (2) | KR102800305B1 (https=) |
| CN (1) | CN111601801A (https=) |
| AU (2) | AU2019206438B2 (https=) |
| BR (1) | BR112020014202A2 (https=) |
| CA (1) | CA3087841A1 (https=) |
| CU (1) | CU24643B1 (https=) |
| EA (1) | EA202091267A1 (https=) |
| IL (1) | IL275952B2 (https=) |
| MX (1) | MX2020007383A (https=) |
| MY (1) | MY200800A (https=) |
| PH (1) | PH12020551062A1 (https=) |
| SG (1) | SG11202005992XA (https=) |
| WO (1) | WO2019138367A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737401A4 (en) * | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025083628A1 (en) | 2023-10-19 | 2025-04-24 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250339404A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE |
| WO2025229631A2 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US8748627B2 (en) * | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| HRP20181052T1 (hr) * | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| ITTO20130731A1 (it) | 2013-09-09 | 2015-03-10 | Indesit Co Spa | Muffola di un forno nella quale sono fissate delle guide |
| NZ734650A (en) * | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| EP3267985A4 (en) * | 2015-03-10 | 2018-07-25 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| BR112017019306A2 (pt) * | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| JP2019502753A (ja) * | 2015-12-23 | 2019-01-31 | ムーンショット ファーマ エルエルシー | ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法 |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| DK3454879T3 (da) | 2016-05-10 | 2022-03-14 | Inst Nat Sante Rech Med | Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| WO2018047139A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| MY205585A (en) | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| EP3737401A4 (en) | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
-
2019
- 2019-01-11 EP EP19738566.9A patent/EP3737401A4/en active Pending
- 2019-01-11 MX MX2020007383A patent/MX2020007383A/es unknown
- 2019-01-11 BR BR112020014202-6A patent/BR112020014202A2/pt unknown
- 2019-01-11 IL IL275952A patent/IL275952B2/en unknown
- 2019-01-11 WO PCT/IB2019/050219 patent/WO2019138367A1/en not_active Ceased
- 2019-01-11 AU AU2019206438A patent/AU2019206438B2/en active Active
- 2019-01-11 KR KR1020207020398A patent/KR102800305B1/ko active Active
- 2019-01-11 KR KR1020257013071A patent/KR20250057146A/ko active Pending
- 2019-01-11 JP JP2020538785A patent/JP7438955B2/ja active Active
- 2019-01-11 MY MYPI2020003578A patent/MY200800A/en unknown
- 2019-01-11 CU CU2020000046A patent/CU24643B1/es unknown
- 2019-01-11 CA CA3087841A patent/CA3087841A1/en active Pending
- 2019-01-11 CN CN201980007859.6A patent/CN111601801A/zh active Pending
- 2019-01-11 US US16/245,860 patent/US11274123B2/en active Active
- 2019-01-11 EA EA202091267A patent/EA202091267A1/ru unknown
- 2019-01-11 SG SG11202005992XA patent/SG11202005992XA/en unknown
-
2020
- 2020-07-10 PH PH12020551062A patent/PH12020551062A1/en unknown
-
2021
- 2021-01-22 US US17/155,242 patent/US11560403B2/en active Active
-
2023
- 2023-01-05 US US18/150,246 patent/US12565515B2/en active Active
- 2023-12-14 JP JP2023211350A patent/JP7698699B2/ja active Active
-
2024
- 2024-03-04 AU AU2024201411A patent/AU2024201411B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019138367A5 (https=) | ||
| JP2021514345A5 (https=) | ||
| JP2024028989A5 (https=) | ||
| TWI309647B (https=) | ||
| IL275952B1 (en) | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signaling Pathways | |
| JP2025160318A5 (https=) | ||
| JP2020125349A5 (https=) | ||
| JP2002332234A5 (https=) | ||
| JP2003520195A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2006514012A5 (https=) | ||
| MXPA04003439A (es) | Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc. | |
| JP2005523922A5 (https=) | ||
| JP2019529444A5 (https=) | ||
| JP2007501809A5 (https=) | ||
| JP2005505618A5 (https=) | ||
| JP2022071077A5 (https=) | ||
| JP2018525405A5 (https=) | ||
| IL273387B2 (en) | Thylanstatin analogs | |
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
| RU99125773A (ru) | N-триазолил-2-индолкарбоксамиды и их применение в качестве агонистов хцк-а | |
| JPWO2020173935A5 (https=) | ||
| JP4312264B2 (ja) | アクリロイル置換ジスタマイシン誘導体、その製造法、および抗腫瘍および抗ウイルス剤としてのその使用 | |
| JP2002525323A5 (https=) | ||
| NO20004162L (no) | Antitumor agens |